No Data
Shanghai Kehua Bio-Engineering, Subsidiaries to Invest 68 Million Yuan for New Unit
Shanghai Kehua Bio-engineering (002022.SZ) plans to establish a subsidiary to undertake the Shaanxi Province High-Performance Diagnostic Medical Instruments Innovation Center project.
Shanghai Kehua Bio-engineering (002022.SZ) has announced the undertaking of the Shaanxi Province High-Performance Diagnostic Medical Instruments Innovation Center project...
shanghai kehua bio-engineering (002022.SZ): not involved in chip R&D business
Shanghai Kehua Bio-engineering (002022.SZ) stated on the investor interaction platform on November 28 that the company's main business is the research and development, production, and sales of in vitro diagnostic reagents and medical testing instruments. The company is not involved in chip business.
Kehua Bio-Engineering Gets Device Registration Certificate for Creatine Kit
Shanghai Kehua Bio-Engineering (002022.SZ): Creatine Kinase Isoenzyme Assay Kit obtained the registration certificate for medical instruments.
Shanghai kehua bio-engineering (002022.SZ) stated on the investor interaction platform today that the company recently obtained a medical device registration certificate (in vitro diagnostic reagent) issued by the Shanghai Municipal Food and Drug Administration. The product is named Creatine Kinase Isoenzyme Assay Kit (Latex Immunoassay), this assay kit is supplied to medical institutions for the quantitative determination of creatine kinase isoenzyme in human serum or plasma samples, clinically used for the auxiliary diagnosis of diseases such as myocardial infarction and myopathy.
shanghai kehua bio-engineering (002022.SZ): The company sells products in Saudi Arabia.
On November 7th, shanghai kehua bio-engineering (002022.SZ) stated on the investor interaction platform that the company sells products in Saudi Arabia, currently on a small scale. The company will continue to consolidate its existing overseas customer network and actively expand overseas markets.
Investors Don't See Light At End Of Shanghai Kehua Bio-Engineering Co.,Ltd's (SZSE:002022) Tunnel And Push Stock Down 26%
